Navigation Links
NxStage Announces Streamline(TM) Blood Tubing Set Supply Agreement with Renal Advantage Inc.

LAWRENCE, Mass., Oct. 21 /PRNewswire-FirstCall/ -- NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems Division has signed a long-term product supply agreement with Renal Advantage Inc. ("RAI"), the fourth largest provider of dialysis services in the United States. Under the terms of this agreement, NxStage will supply the Streamline(TM) airless blood tubing set as well as MasterGuard and other products to RAI's dialysis center network.

"RAI has been a strong strategic partner in expanding availability of daily home hemodialysis therapy with NxStage's System One, and a long-term customer of our Medisystems Division. We are delighted that RAI has chosen to integrate the Streamline product into its in-center operations, and to broaden their commitment to our products," said Jeffrey H. Burbank, President and Chief Executive Officer of NxStage Medical. "By expanding relationships with highly regarded organizations like RAI, NxStage continues to demonstrate our ability to effectively educate the market on the compelling benefits that products like Streamline deliver."

"Streamline is yet another example of NxStage's ability to innovate and bring value to our organization. As part of a diligent evaluation process in our centers, Streamline showed its ability to improve patient clearances, reduce costs, and enhance staff satisfaction," stated Dean Weiland, COO of RAI. "We are pleased to broaden this relationship and be part of NxStage's continued pioneering work in both home hemodialysis and the in-center market."

NxStage's latest generation blood tubing set is the Streamline(TM), an efficient and airless tubing set configuration that improves clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, and treatment time; minimize heparin and waste; and optimize dose delivery, as measured in Kt/V. In recent NxStage evaluations, centers were able to increase their patient dialysis dose delivery and increase minimum Kt/V of 1.2 to 98% of their in center patients -- clearly exceeding industry standards that tout Kt/V of 1.2 for 93% of patients. This is a key measure for in-center therapy. Streamline also includes our patented LockSite(TM) needleless access ports, which eliminate the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative products for the treatment of ESRD and acute kidney failure. For more information on NxStage and its products, please visit the company's website at

About Renal Advantage

Based in Brentwood, Tennessee, Renal Advantage Inc. provides dialysis services to patients with chronic kidney failure, also known as end-stage renal disease (ESRD). Renal Advantage provides services to over 8,200 patients in 91 dialysis centers in ten states and delivers laboratory services through RenaLab, a state-of-the-art independent clinical laboratory located in Jackson, MS. Founded by veteran healthcare executives, the Company's growth plan began with its acquisition of 73 dialysis centers in October 2005, which was financed in partnership with Welsh, Carson, Anderson & Stowe. For more information, visit the Company's website at

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including, but not limited to, changes relating to customer demand for NxStage's blood tubing sets and other products and other factors that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.


Kristen K. Sheppard, Esq.

VP, Investor Relations

SOURCE NxStage Medical, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. NxStage Medical to Present at the Thomas Weisel Partners Healthcare Conference on September 5, 2007
2. NxStage Medical Provides Update on Medisystems Acquisition
3. NxStage(R) Medical to Report Third Quarter 2007 Financial Results on Friday, November 2nd
4. Arbios Announces SEPET(TM) Manufacturing Agreement With NxStage Medical
5. NxStage Medical to Present at the Piper Jaffray Healthcare Conference on November 27, 2007
6. NxStage Medical Announces Needle Supply Agreement with DaVita
7. NxStage Appoints Tom Shea as Senior Vice President of Manufacturing Operations
8. NxStage Medical to Present at William Blair Growth Stock Conference
9. NxStage Announces Access to Demographic and Outcomes Information for the Growing U.S. Daily Home Hemodialysis Patient Population
10. NxStage Announces Investor Conference Schedule
11. NxStage Medical to Present at JMP Securities Healthcare Focus Conference
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... This fall, global software solutions leader SAP and ... to develop and pitch their BIG ideas to improve health and wellness in their ... votes to win the title of SAP's Teen Innovator, an all-expenses paid trip to ...
(Date:11/24/2015)... New York , November 24, 2015 ... to a recent market research report released by Transparency ... projected to expand at a CAGR of 17.5% during ... "Non-invasive Prenatal Testing Market - Global Industry Analysis, Size, ... estimates the global non-invasive prenatal testing market to reach ...
(Date:11/24/2015)...  Twist Bioscience, a company focused on synthetic ... Bioscience chief executive officer, will present at the ... 2015 at 3:10 p.m. Eastern Time at The Lotte New ... --> --> About Twist ... on Twitter. Sign up to follow our Twitter ...
(Date:11/24/2015)... Vancouver, BC (PRWEB) , ... November 24, 2015 ... ... to our customer, OrthoAccel® Technologies, Inc., on being named to Deloitte's 2015 Technology ... Creation Technologies’ Texas facility, OrthoAccel manufactures AcceleDent®, a FDA-cleared, Class II medical device ...
Breaking Biology Technology:
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  The J. Craig Venter ... titled, "DNA Synthesis and Biosecurity: Lessons Learned and Options ... of Health and Human Services guidance for synthetic biology ... --> --> ... has the potential to pose unique biosecurity threats. It ...
(Date:10/29/2015)... 2015  Rubicon Genomics, Inc., today announced an ... its DNA library preparation products, including the ThruPLEX ... Plasma-seq kit. ThruPLEX Plasma-seq has been optimized for ... libraries for liquid biopsies--the analysis of cell-free circulating ... in cancer and other conditions. Eurofins Scientific is ...
Breaking Biology News(10 mins):